InMed Announces Update on Biosynthesis Project

Vancouver, BC - February 16, 2016 - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today an update on its biosynthesis program. 

The goal of InMed's biosynthesis program is to provide an alternate low cost and high quality process for producing phytocannabinoids for its product candidates. Typically, phytocannabinoids are extracted from the cannabis plant. The extraction process can be expensive, and can result in unwanted by-products and impurities. Using metabolic engineering the plant pathway for producing cannabinoids can be recreated in a microbial host and will be devoid of the by-products and impurities seen with extraction. The process can also be performed at industrial-scale allowing for a low cost production of cannabinoids. 

Dr. Sazzad Hossain states "We have made great progress in the last 8 months developing a comprehensive de novo biosynthesis system for cannabinoids using a multiple metabolic engineering approach and have been able to produce our target cannabinoids on a gram scale basis. Successful production of our target cannabinoids using a biosynthetic process is a significant achievement for InMed and is an important step for our product development program". 

InMed has filed a patent application covering its inventions in the organic and enzymatic synthesis of cannabinoids.

To review a presentation on InMed's biosynthesis program please click here:

About Metabolic Engineering

Metabolic engineering can be defined as the modification of a cell's metabolic network for increased production of a specific molecule. Metabolic engineering simply re-creates the plant pathway in a microbial host, thereby allowing industrial-scale exploitation of the pathway for production of natural products. Many of pitfalls associated with plant extraction techniques are avoided. Importantly, unlike plant extraction, metabolic engineering allows manipulation of the pathway composition to tweak the final composition of the products. Not only is it a higher-yielding and more resource-efficient manufacturing platform, but the bioprocess and products face less obstacles when it comes to regulatory approval.

About InMed 

InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. 

For more information, visit

Contact: InMed Pharmaceuticals Inc.

Paul Brennan
President and Chief Executive Officer 
T: 604.669.7207


Chris Bogart
SVP, Corporate Strategy and Investor Relations
T: 604.669.7207

Cautionary Note Regarding Forward-Looking Information

Forward Looking Statements

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.